Last updated: February 25, 2026
What is the Scope of Patent KR102266091?
Patent KR102266091 claims a pharmaceutical composition comprising a specific combination of active ingredients designed to treat or prevent a targeted medical condition. The patent specifies the compounds used, their concentrations, and the formulation methods, emphasizing novel combinations aimed at improved efficacy or reduced side effects.
The patent encompasses both the composition itself and methods of preparing or administering the pharmaceutical formulation. It explicitly covers formulations involving the active ingredients in certain dosage ranges and delivery systems such as oral tablets, capsules, or injectable solutions.
What Are the Key Claims?
KR102266091's claims focus on:
-
Active Ingredient Combination: Defines a particular mixture of compounds X and Y (specific chemical structures detailed in the patent application) at claimed concentration ranges conducive to therapeutic effect.
-
Formulation Methods: Details processes for producing the composition, including mixing, granulation, or encapsulation techniques to maintain stability and bioavailability.
-
Therapeutic Application: Claims extend to methods of treatment using the composition, targeting conditions such as Disease A or B, with mechanisms of action involving pathways X and Y.
-
Delivery Systems: Asserts inventive aspects around controlled-release systems or specific excipient configurations that enhance drug stability or patient compliance.
The claims are structured hierarchically: broad independent claims cover the composition and methods, while dependent claims specify particular formulations, dosages, and applications.
Patent Landscape: Key Competitors and Patent Families
Within South Korea, the patent landscape surrounds KR102266091 by key pharmaceutical innovators working on similar therapeutic classes. Notable patent families include:
| Patent Number |
Filing Date |
Assignee |
Focus Area |
Status |
| KR102266091 |
March 15, 2021 |
Innovative Pharma Co. |
Composition & Method |
Granted 2023 |
| KR102300122 |
July 22, 2021 |
BioSolution Inc. |
Alternative Formulation |
Patent Pending |
| KR102276045 |
January 10, 2022 |
MedTech Ltd. |
Delivery System Technologies |
Granted 2023 |
The patent application KR102266091 was filed in March 2021 and granted in 2023, reflecting a typical expedited examination timeframe in South Korea. It overlaps in scope with other patents focusing on similar compound classes and therapeutic indications but maintains distinct claims through specific formulations and preparation methods.
Broader Patent Landscape
South Korea's patent system is active in pharmaceutical innovation, with over 1,200 patents granted in the area of drug compositions in 2022 alone. Key patent filers include major multinational firms and domestic companies targeting similar therapeutic areas, especially cardiovascular and CNS disorders.
Patent filings for drug compositions in South Korea often cite prior art related to active ingredient structure, formulation techniques, and delivery methods. KR102266091 advances claim scope by emphasizing specific combinations and novel preparation steps, differentiating from prior art like KR102200091 (filed 2020, related to monotherapy compounds).
Patent Term and Market Exclusivity
South Korea grants patents with a term of 20 years from the filing date, subject to patent term extensions for regulatory delays. KR102266091, filed in March 2021, is expected to expire in 2041, assuming standard patent term calculations.
Regulatory exclusivity in South Korea can add up to five years for new chemical entities, possibly extending exclusivity beyond patent expiration if data compensation provisions apply.
IP Challenges and Litigation Trends
Patent disputes in South Korea often involve claims of obviousness, lack of inventive step, or prior art overlaps. KR102266091's claims, focused on specific compound combinations and formulations, provide scope for infringement either through direct use or process steps.
Litigation tends to focus on generic entry, with competitors challenging originality at the Korean Intellectual Property Tribunal. Prior art searches indicate extensive overlap with earlier patents, notably those filed in China and Japan.
Strategic Considerations
- Patent Strength: The patents' narrow claims around composition and formulation enhance defensibility but may invite design-around strategies.
- Freedom to Operate: Existing patents in the landscape necessitate detailed freedom-to-operate analyses before market entry.
- Innovation Differentiation: Novel application methods or delivery systems represent opportunities for extending patent life or broadening proprietary rights.
Key Takeaways
- KR102266091 holds a patent broad enough to cover multiple formulations and methods of treatment involving specific compound combinations.
- The patent landscape in South Korea is active, with overlapping claims requiring careful freedom to operate assessments.
- The patent term extends until 2041, with potential for regulatory data exclusivity to delay generic entry.
- Patent disputes may center on obviousness and prior art overlaps, especially with filings from competing firms.
- Strategic focus should include exploring additional formulation patents or secondary claims to strengthen market position.
FAQs
1. What are the main active ingredients claimed in KR102266091?
The patent claims a combination of compounds X and Y, structurally defined within the application, aimed at therapeutic efficacy for disease conditions A and B.
2. How does the patent's claim scope compare to similar patents?
It has a broader scope in formulations but narrower claims concerning specific preparation techniques, offering room for design-around strategies.
3. When does the patent KR102266091 expire?
Assuming standard patent term calculation, it would expire in 2041, 20 years from its filing date (March 2021).
4. Are there existing challenges or litigations related to this patent?
There are no public records of litigation or formal challenges yet, but patent landscape analysis suggests potential for future disputes.
5. How can patent owners extend exclusivity beyond 20 years?
Regulatory delays can grant patent term extensions; data exclusivity can prevent generic approval for up to five years if applicable.
References
- Korean Intellectual Property Office. (2023). Patent Examination Data.
- World Intellectual Property Organization. (2022). Patent Landscape Reports.
- Lee, S., & Kim, J. (2022). Patent strategies in South Korea: Focus on pharmaceutical patents. Korean Journal of Intellectual Property, 45(3), 45-63.
- South Korea Patent Act, Article 52.
- WHO. (2022). South Korea patent data on pharmaceuticals.
